Evidence map›Paper›PMID 34693876›Full record

ArticlePharmaceutical biology2021

Huaiqihuang (HQH) granule alleviates cyclophosphamide-induced nephrotoxicity via suppressing the MAPK/NF-κB pathway and NLRP3 inflammasome activation.

Yueming Zhang, Jian Chang, Huan Gao, Xiaoyu Qu, Jinghui Zhai, Lina Tao, Jingmeng Sun, Yanqing Song

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Involvement of the SIRT1-NLRP3 pathway in the inflammatory response.Cell communication and signaling : CCS · 2023
    Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yueming ZhangDepartment of Pharmacy, the First Hospital of Jilin University, Changchun, China.
Jian ChangDepartment of Pediatric Oncology, the First Hospital of Jilin University, Changchun, China.
Huan GaoDepartment of Pharmacy, the First Hospital of Jilin University, Changchun, China.
Xiaoyu QuDepartment of Pharmacy, the First Hospital of Jilin University, Changchun, China.ORCID 0000-0003-1685-6914
Jinghui ZhaiDepartment of Pharmacy, the First Hospital of Jilin University, Changchun, China.
Lina TaoDepartment of Pharmacy, the First Hospital of Jilin University, Changchun, China.
Jingmeng SunDepartment of Pharmacy, the First Hospital of Jilin University, Changchun, China.
Yanqing SongDepartment of Pharmacy, the First Hospital of Jilin University, Changchun, China.
Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextSevere nephrotoxicity greatly limits the clinical use of the common effective chemotherapeutic agent cyclophosphamide (CYP). Huaiqihuang (HQH) is a Chinese herbal complex with various pharmacological activities, widely used for treating kidney disease.

objectiveThis study estimates the protective effect of HQH against CYP-induced nephrotoxicity in rats. MATERIALS AND

methodsFour groups of 10 Sprague-Dawley rats were pre-treated with once-daily oral gavage of 3 and 6 mg/kg HQH for 5 days before receiving a single dose of CYP (200 mg/kg i.p.) on the 5th day; the control group received equivalent dose of saline. Renal function indices, morphological changes, oxidative stress, apoptosis and inflammatory mediators were measured. In addition, phosphorylation of the NF-κB/MAPK pathway and the activation of the NLRP3 inflammasome were analysed.

resultsBoth doses of HQH reduced the levels of serum creatinine (31.27%, 43.61%), urea nitrogen (22.66%, 32.27%) and urine protein (12.87%, 15.98%) in the CYP-treated rats, and improved histopathological aberrations. Additionally, HQH decreased the production of MDA (37.02%, 46.18%) and increased the activities of antioxidant enzyme CAT (59.18%, 112.25%) and SOD (67.10%, 308.34%) after CYP treatment. HQH protected against CYP-induced nephrotoxicity by modulating apoptosis-related protein and suppressing the inflammatory responses. Furthermore, the phosphorylation of the NF-κB/MAPK pathway and the activation of the NLRP3 inflammasome were significantly boosted in CYP-treated rats, which was also abrogated by HQH treatment.

conclusionsHQH effectively protected against CYP-induced nephrotoxicity, which was associated with regulating oxidative stress, apoptosis and inflammation, and so HQH may be a useful agent for treating nephrotoxicity caused by CYP.

Indexed as

AnimalsAntineoplastic Agents, AlkylatingApoptosisCyclophosphamideDrugs, Chinese HerbalInflammasomesInflammationKidney DiseasesMaleMAP Kinase Signaling SystemNF-kappa BNLR Family, Pyrin Domain-Containing 3 ProteinOxidative StressRatsRats, Sprague-DawleyAntineoplastic Agents, AlkylatingCyclophosphamideDrugs, Chinese Herbalhuai qi huangInflammasomesNF-kappa BNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, ratapoptosischemotherapeutic agentChinese medicineinflammationoxidative stress

Identifiers

PMID34693876
PMCPMC8547856
OpenAlexW3208589741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.